Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Design Therapeutics, Inc.DSGN · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $226.2M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsshort runway, thin data, degenerate inputsnot computable: fortress balance sheet
Inputs computable6 of 14
Graded fromfilings received through Mar 9, 2026214 days before the rescan; every figure keyed to the SEC receipt date
Last close$11.472026-10-08; market equity $718.1M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$5$10$15NovDecJanFebMarAprMayJunJulAugSepOct$11.49
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2022nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 9, 2026; the document on sec.gov.

As used in this Annual Report on Form 10-K, unless the context indicates or otherwise requires, “Design,” “our company,” “we,” “us,” and “our” refer to Design Therapeutics, Inc., a Delaware corporation. We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.

Warnings [top]

Short runway. cash runway is 2.8 months[3]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 57.0
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(6.5%)[1,4-6](6.6%)57.08112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 10.7
Twelve-month failure probability0.04%0.07%22.72482026-06-30
Altman Z double-prime15.76[1,7-12](0.31)4.17562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio17.14x[7-8]2.96x5.38392025-12-31
Growth and financing, sleeve percentile 61.0
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 2
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(12.8%)[1,6,13-14]2.1%72.77042025-12-31
Net share issuance, one year8.6%[15-16]2.5%49.36342026-03-02

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month100.4%8.0%88hotter than 88 of 100 peers
Distance from 52-week high(27.9%)(31.4%)55closer to its high than 55 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(7.6%)(1.0%)36pricier than 64 of 100 peers
Book value to price0.280.2850pricier than 50 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five yearsnot computable20.3%a share count from five years earlier is required
Relative strength against the sector, log excess return0.48(0.14)88ahead of 88 of 100 peers

Inputs: market equity $719.1M; EBIT -$79.5M; free cash flow -$54.6M; book equity $201.9M; sales $0; cash $12.9M[17].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(27.7%)✗ fail[4,6]
Operating cash flow above zero-$54.4M✗ fail[5]
Return on assets improved(10.6 pts)✗ fail[4,6,13,18]
Operating cash flow exceeds net income$15.4M✓ pass[4-5]
Long-term leverage felln/a[1,6,13]
Current ratio improved(1,217.1 pts)✗ fail[7-8,19-20]
No new shares issued8.6%✗ fail[15-16]
Gross margin improvedn/a
Asset turnover improved0.0 pts✗ fail[2,6,13,21]
Cash, filings, liquidity
Cash and equivalents$12.9M[3]
Operating cash flow, four quarters-$55.1M[3,5,22-25]
Months of runway2.8
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing67
10-Q received Aug 3, 2026
Median daily dollar volume$7.0M
63 sessions
Days since newest grade input214

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$226.2M2025-12-312026-03-0910-Kfiling · viewer · series
2revenueus-gaap:Revenues$02025-12-312026-03-0910-Kfiling · viewer · series
3cashus-gaap:CashAndCashEquivalentsAtCarryingValue$12.9M2026-06-302026-08-0310-Qfiling · viewer · series
4net incomeus-gaap:NetIncomeLoss-$69.8M2025-12-312026-03-0910-Kfiling · viewer · series
5operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$54.4M2025-12-312026-03-0910-Kfiling · viewer · series
6assetsus-gaap:Assets$252.1M2024-12-312026-03-0910-Kfiling · viewer · series
7current assetsus-gaap:AssetsCurrent$223.8M2025-12-312026-03-0910-Kfiling · viewer · series
8current liabilitiesus-gaap:LiabilitiesCurrent$13.1M2025-12-312026-03-0910-Kfiling · viewer · series
9retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$297.0M2025-12-312026-03-0910-Kfiling · viewer · series
10operating incomeus-gaap:OperatingIncomeLoss-$79.5M2025-12-312026-03-0910-Kfiling · viewer · series
11book equityus-gaap:StockholdersEquity$212.5M2025-12-312026-03-0910-Kfiling · viewer · series
12liabilitiesus-gaap:Liabilities$13.7M2025-12-312026-03-0910-Kfiling · viewer · series
13assetsus-gaap:Assets$289.6M2023-12-312025-03-1010-Kfiling · viewer · series
14assetsus-gaap:Assets$341.1M2022-12-312024-03-1910-Kfiling · viewer · series
15shares outstandingdei:EntityCommonStockSharesOutstanding61,672,2792026-03-022026-03-0910-Kfiling · viewer · series
16shares outstandingdei:EntityCommonStockSharesOutstanding56,762,6782025-03-062025-03-1010-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding62,581,6512026-07-292026-08-0310-Qfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$49.6M2024-12-312026-03-0910-Kfiling · viewer · series
19current assetsus-gaap:AssetsCurrent$248.0M2024-12-312026-03-0910-Kfiling · viewer · series
20current liabilitiesus-gaap:LiabilitiesCurrent$8.5M2024-12-312026-03-0910-Kfiling · viewer · series
21revenueus-gaap:Revenues$02024-12-312025-03-1010-Kfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$32.0M2026-06-302026-08-0310-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$16.4M2026-03-312026-04-2810-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$42.4M2025-09-302025-11-0510-Qfiling · viewer · series
25operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$31.2M2025-06-302026-08-0310-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.